Get the app
USTechnology

Novanta Inc (NOVT)

US · Technology · Scientific & Technical Instruments

$133.55+0.56%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$265.8M
Revenue YoY
+10.3%
Net profit
$12.5M
Profit YoY
+178.9%
EPS
$0.89
EPS estimate
$0.83
Net margin
4.7%

EPS came in at 0.89 against a street estimate of 0.83 — a beat of 7.2%.

Key statistics

Market cap
$5.54B
P/E
92.8
Forward P/E
8.4
P/B
3.43
Book value
$42.74
EPS (TTM)
$1.58
52-week high
$176.38
52-week low
$98.27
50-day MA
$150.10
200-day MA
$138.50
Beta
1.68

Analyst view

Analysts rate Novanta Inc a buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $194.50.

From the latest earnings call · 2026-08-06

CONFIDENT Q2 beat expectations: 9% organic growth, 47% gross margin (+100bps YoY), 16% EBITDA growth. Closed transformative Riverpoint Medical acquisition. Raised FY26 guidance to 15%+ reported growth. All segments grew organically. Q2 2026 Not discussed by geography; Medical 51% of sales, Advanced Industrial 49%. Analysts pressed on Gen AI visibility into 2027 (management confident mid-20% growth continuing, air spindles booked 2 years out), advanced surgery booking timing (management noted 4-Q rolling average >1.0, full-year book-to-bill >1.0), and core margin algorithm (management expects 48% in 2027 despite tariff/inflation headwinds, site closures driving improvement). 2026-08-06…

Full summary in the app.

Shareholding

Insiders
0.71%
Institutions
123.45%

Largest institutional holders

FundStake
BlackRock Inc12.31%
Vanguard Portfolio Management, LLC6.55%
Allspring Global Investments Holdings, LLC4.81%
T. Rowe Price Associates, Inc.4.72%
Vanguard Capital Management, LLC4.27%
State Street Corp3.54%
Conestoga Capital Advisors, LLC3.22%
Congress Asset Management Company, LLP2.57%

Recent filings & reports

DocumentDate
Quarterly report · Q3 2026
NOVANTA INC. - 10-Q SUMMARY (July 3, 2026) HEADLINE NUMBERS • Revenue Q2 2026: $265.8 million (up 10.3% vs. Q2 2025: $241.0 million) • Revenue H1 20
2026-08-05
Results announced · Q3 2026
NOVANTA INC. – Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 GAAP revenue: $265.8 million, up 10.3% year-over-year ($24.8 million increase) •
2026-08-05
Acquisition completed · Q3 2026
NOVANTA INC. - 8-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Acquisition closed July 23, 2026: Novanta completed purchase of Runway Buyer LLC
2026-07-27
Material agreement · Q2 2026
NOVANTA INC. - 8-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Private placement size: $300.0 million in gross proceeds • Share price in placeme
2026-06-09
Material agreement · Q2 2026
NOVANTA INC. – 8-K SUMMARY HEADLINE NUMBERS • Acquisition price: $1,200,000,000 in cash at closing (subject to working capital and debt adjustments)
2026-06-09
Quarterly report · Q2 2026
NOVANTA INC. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue: $257.7 million (Q1 2026) vs. $233.4 million (Q1 2025) — up 10.4% year-over-year • Ne
2026-05-11
Proxy statement · Q2 2026
NOVANTA INC. PROXY STATEMENT SUMMARY CEO COMPENSATION • Matthijs Glastra (Chair and CEO) total compensation for fiscal year 2025: $7,356,000 • Compe
2026-04-24
Annual report FY2025
NOVANTA INC. — 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Total Revenue (2025): $980.6 million across two segments - Automation Enabling
2026-02-23

Readable in the app.

Deals & corporate news

AnnouncementDate
Completed acquisition of Riverpoint Medical from Arlington Capital Partners
Novanta Inc. completed its acquisition of Riverpoint Medical, a leading manufacturer of minimally invasive surgical consumables (surgical fibers for sports medicine, trauma, and cardiovascul
2026-07-27
Equity purchase agreement to acquire business from Runway Midco
Novanta Inc. is acquiring Runway Buyer, LLC (owned by Runway Midco, LLC) through its subsidiary Novanta Medical Technologies Corp. This is a strategic acquisition in the medical technology s
2026-06-09
Revised Q4 and full year 2025 EPS guidance down due to equity issuance
Novanta Inc. completed a recent equity issuance (stock offering) and revised its 2025 earnings guidance downward to reflect share dilution. The company lowered its adjusted diluted earnings
2025-11-13
Board authorizes additional $200 million share repurchase program
Novanta Inc.'s Board of Directors authorized an additional $200 million share repurchase program on September 18, 2025. Combined with the $31 million remaining from a previous 2020 authoriza
2025-09-18

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Novanta Inc — free to start.

Google PlayApp Store

Other Technology companies

Data updated 2026-09-18.